Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate.

RATIONALE Retrospective pharmacogenetic studies have questioned whether patients with asthma who are arginine homozygous at the beta(2-)adrenergic receptor (position 16) should use long-acting beta-agonists. OBJECTIVES To examine whether the response to salmeterol alone or in combination with an inhaled corticosteroid is influenced by beta- receptor polymorphisms. METHODS Subjects using only as-needed albuterol were screened and completed two sequential open-label run-in periods (8 wk on as-needed albuterol; 8 wk on as-needed ipratropium). Five hundred forty-four subjects were randomized by Arg16Gly genotype to salmeterol alone or with fluticasone propionate for 16 weeks. Change from baseline in morning peak expiratory flow was the primary endpoint. MEASUREMENTS AND MAIN RESULTS Lung function responses were sustained over treatment and no statistically significant changes from baseline between genotypes within treatments were observed. Overall mean changes in morning peak flow for salmeterol with fluticasone propionate were 32.6 L/min (Arg/Arg vs. Gly/Gly, 95% confidence interval [CI], -6.3, 22.1), 25.9 L/min (Arg/Arg vs. Arg/Gly, 95% CI, -7.1, 21.3), and 24.9 L/min (Arg/Gly vs. Gly/Gly, 95% CI, -13.0, 14.6), and for salmeterol alone were 19.4 L/min (Arg/Arg vs. Gly/Gly, 95% CI, -1.7, 21.4), 24.6 L/min (Arg/Arg vs. Arg/Gly, 95% CI, -13.0, 10.6), and 12.4 L/min (Arg/Gly vs. Gly/Gly, 95% CI, -0.2, 22.3) for Arg/Arg, Arg/Gly, and Gly/Gly genotypes, respectively. Other measures of asthma control showed similar responses. CONCLUSIONS The results showed no evidence of a pharmacogenetic effect of beta-receptor variation on salmeterol response. Clinical trial registered with www.clinicaltrials.gov (NCT 00102882).

[1]  E. Bleecker,et al.  Characterization of Asthma Exacerbations by Arg16Gly Genotype in Subjects with Asthma Receiving Salmeterol Alone or with Fluticasone Propionate , 2008 .

[2]  E. Bleecker,et al.  Arg16Gly Polymorphism of the β2-adrenergic Receptor Gene Does Not Modulate Clinical Response to Salmeterol in Subjects with Asthma , 2008 .

[3]  E. Bleecker,et al.  Lack of Effect of Promoter, Coding and 3′ Polymorphisms of the β2-adrenergic Receptor (ADRB2) on the Clinical Response to Salmeterol Alone or with Fluticasone Propionate in Subjects with Asthma , 2008 .

[4]  E. Bleecker,et al.  Variable-length poly-C tract polymorphisms of the beta2-adrenergic receptor 3'-UTR alter expression and agonist regulation. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[5]  I. Hall,et al.  ADRB2 polymorphisms and β2 agonists , 2007, The Lancet.

[6]  D. Postma,et al.  Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies , 2007, The Lancet.

[7]  E. Bleecker,et al.  ARGININE 16 GENOTYPE DOES NOT MODULATE CLINICAL RESPONSE TO SALMETEROL IN SUBJECTS WITH ASTHMA , 2007 .

[8]  I. Sayers,et al.  Pharmacogenetics and asthma: false hope or new dawn? , 2007, European Respiratory Journal.

[9]  D. Mannino,et al.  ADRB2 Arg16Gly Polymorphism, Lung Function, and Mortality: Results from the Atherosclerosis Risk in Communities Study , 2007, PloS one.

[10]  Deborah A Meyers,et al.  Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. , 2006, American journal of respiratory and critical care medicine.

[11]  L. Edwards,et al.  Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. , 2006, The Journal of allergy and clinical immunology.

[12]  R. Lipchik.  Addition of salmeterol to usual asthma pharmacotherapy may increase respiratory related deaths or life threatening experiences , 2006, Evidence-based medicine.

[13]  Vernon M. Chinchilli,et al.  β-Adrenergic Receptor Polymorphisms and Response to Salmeterol , 2006 .

[14]  Jianwei Wang,et al.  The C523A β2 Adrenergic Receptor Polymorphism Associates with Markers of Asthma Severity in African Americans , 2006, The Journal of asthma : official journal of the Association for the Care of Asthma.

[15]  P. Dorinsky,et al.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.

[16]  Sang-Heon Cho,et al.  Association between bronchodilating response to short‐acting β‐agonist and non‐synonymous single‐nucleotide polymorphisms of β2‐adrenoceptor gene , 2005 .

[17]  E. Boerwinkle,et al.  Interactive effects between polymorphisms in the beta-adrenergic receptors and longitudinal changes in obesity. , 2005, Obesity research.

[18]  E. Israel,et al.  Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial , 2004, The Lancet.

[19]  I. Hall,et al.  The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. , 2003, British journal of clinical pharmacology.

[20]  D. Schaid,et al.  Score tests for association between traits and haplotypes when linkage phase is ambiguous. , 2002, American journal of human genetics.

[21]  E. Israel,et al.  Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. , 2001, JAMA.

[22]  R S Judson,et al.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Drazen,et al.  Asthma exacerbations during long term â agonist use : influence of â 2 adrenoceptor polymorphism , 2000 .

[24]  E. Silverman,et al.  The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. , 2000, American journal of respiratory and critical care medicine.

[25]  R Judson,et al.  The predictive power of haplotypes in clinical response. , 2000, Pharmacogenomics.

[26]  D. Thomason,et al.  Impact of genetic polymorphisms of the β2‐adrenergic receptor on albuterol bronchodilator pharmacodynamics , 1999, Clinical pharmacology and therapeutics.

[27]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[28]  R. Erickson,et al.  Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. , 1997, The Journal of clinical investigation.

[29]  Brian Lipworth,et al.  Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics , 1997, The Lancet.

[30]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[31]  J Crane,et al.  End of the New Zealand asthma mortality epidemic , 1995, The Lancet.

[32]  W. Castle,et al.  Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. , 1993, BMJ.

[33]  S. Liggett,et al.  Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. , 1993, American journal of respiratory cell and molecular biology.

[34]  Pierre Ernst,et al.  The Use of β-Agonists and the Risk of Death and near Death from Asthma , 1992 .

[35]  C. Print,et al.  Regular inhaled beta-agonist treatment in bronchial asthma , 1990, The Lancet.

[36]  Stolley Pd.  Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. , 1972 .